

Alma Mater Studiorum Università di Bologna  
Archivio istituzionale della ricerca

Cardiac Surgery in Patients With Liver Cirrhosis (CASTER) Study: Early and Long-Term Outcomes

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

*Published Version:*

Garatti, A., Dapratì, A., Cottini, M., Russo, C.F., Dalla Tomba, M., Troise, G., et al. (2021). Cardiac Surgery in Patients With Liver Cirrhosis (CASTER) Study: Early and Long-Term Outcomes. ANNALS OF THORACIC SURGERY, 111(4), 1242-1251 [10.1016/j.athoracsur.2020.06.110].

*Availability:*

This version is available at: <https://hdl.handle.net/11585/807184> since: 2021-02-26

*Published:*

DOI: <http://doi.org/10.1016/j.athoracsur.2020.06.110>

*Terms of use:*

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.


This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).  
When citing, please refer to the published version.

(Article begins on next page)

# Journal Pre-proof

Cardiac Surgery in Patients with Liver Cirrhosis (CASTER) study: early and long-term outcomes

Andrea Garatti, MD, PhD, Andrea Dapratì, MD, Marzia Cottini, MD, PhD, Claudio F. Russo, MD, Margherita Dalla Tomba, MD, Giovanni Troise, MD, Antonio Salsano, MD, Francesco Santini, MD, Roberto Scrofani, MD, Francesca Nicolò, MD, Elisa Mikus, MD, Alberto Albertini, MD, Luca Di Marco, MD, Davide Pacini, MD, Marco Picichè, MD, PhD, Loris Salvador, MD, Guglielmo M. Actis Dato, MD, Paolo Centofanti, MD, Domenico Paparella, MD, Giorgios Kounakis, MD, Alessandro Parolari, MD, Lorenzo Menicanti, MD, On behalf of the Italian Group of Research for Outcome in Cardiac Surgery(GIROC)



PII: S0003-4975(20)31462-4

DOI: <https://doi.org/10.1016/j.athoracsur.2020.06.110>

Reference: ATS 34236

To appear in: *The Annals of Thoracic Surgery*

Received Date: 5 March 2020


Revised Date: 22 May 2020

Accepted Date: 26 June 2020

Please cite this article as: Garatti A, Dapratì A, Cottini M, Russo CF, Tomba MD, Troise G, Salsano A, Santini F, Scrofani R, Nicolò F, Mikus E, Albertini A, Di Marco L, Pacini D, Picichè M, Salvador L, Actis Dato GM, Centofanti P, Paparella D, Kounakis G, Parolari A, Menicanti L, On behalf of the Italian Group of Research for Outcome in Cardiac Surgery(GIROC), Cardiac Surgery in Patients with Liver Cirrhosis (CASTER) study: early and long-term outcomes, *The Annals of Thoracic Surgery* (2020), doi: <https://doi.org/10.1016/j.athoracsur.2020.06.110>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.





**THE ANNALS OF  
THORACIC SURGERY**

Official Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association

Garatti et al



@annalsthorsurg #TSSMN  
 #VisualAbstract #AnnalsImages



## Cardiac Surgery in Patients with Liver Cirrhosis (CASTER) study: early and long-term outcomes

Running Head: Cardiac Surgery in Cirrhotic Patients

<sup>1</sup>Andrea Garatti, MD,PhD; <sup>1</sup>Andrea Daprati, MD; <sup>2</sup>Marzia Cottini, MD,PhD; <sup>2</sup>Claudio F. Russo, MD; <sup>3</sup>Margherita Dalla Tomba, MD; <sup>3</sup>Giovanni Troise, MD; <sup>4</sup>Antonio Salsano, MD; <sup>4</sup>Francesco Santini, MD; <sup>5</sup>Roberto Scrofani, MD; <sup>5</sup>Francesca Nicolò, MD; <sup>6</sup>Elisa Mikus, MD; <sup>6</sup>Alberto Albertini, MD; <sup>7</sup>Luca Di Marco, MD; <sup>7</sup>Davide Pacini, MD; <sup>8</sup>Marco Picichè, MD,PhD; <sup>8</sup>Loris Salvador, MD; <sup>9</sup>Guglielmo M. Actis Dato, MD; <sup>9</sup>Paolo Centofanti, MD; <sup>10-11</sup>Domenico Paparella, MD; <sup>11</sup>Giorgios Kounakis, MD; <sup>12</sup>Alessandro Parolari, MD and <sup>1</sup>Lorenzo Menicanti, MD On behalf of the Italian Group of Research for Outcome in Cardiac Surgery(GIROC)

<sup>1</sup>Cardiac Surgery Division, IRCCS Policlinico San Donato, San Donato Milanese, Milan - Italy;

<sup>2</sup>Cardiac Surgery Division, ASST Grande Ospedale Metropolitano Niguarda, Milan – Italy

<sup>3</sup>Cardiac Surgery Division, Poliambulanza Foundation Hospital, Brescia – Italy

<sup>4</sup>Cardiac Surgery Division, IRCCS Ospedale Policlinico San Martino, Department of Integrated Surgical and Diagnostic Sciences (DISC), University of Genoa - Italy

<sup>5</sup>Cardiac Surgery Division, ASST Fatebenefratelli Sacco, Milan – Italy

<sup>6</sup>Cardiac Surgery Division, Maria Cecilia Hospital GVM for Care & Research, Cotignola – Italy

<sup>7</sup>Cardiac Surgery Division, Cardio-Thoracic-Vascular Department, S. Orsola Hospital, University of Bologna, Bologna - Italy

<sup>8</sup>Cardiac Surgery Division, San Bortolo Hospital, Vicenza – Italy

<sup>9</sup>Cardiac Surgery Division, Mauriziano Hospital, Turin – Italy

<sup>10</sup>Department of Emergency and Organ Transplant, University of Bari Aldo Moro, Bari Italy

<sup>11</sup>Cardiac Surgery Division, Santa Maria Hospital, GVM Care & Research, Bari – Italy

<sup>12</sup>Universitary Cardiac Surgery, IRCCS Policlinico San Donato and University of Milan– Italy

### Corresponding author:

**Andrea Garatti, MD**, Cardiac Surgery Department “E. Malan”, IRCCS Policlinico S. Donato, Via Morandi 30, 20097 S. Donato Milanese, Milan, Italy.

E-mail: [andrea.garatti@grupposandonato.it](mailto:andrea.garatti@grupposandonato.it)

**Word Count:** 4476

**Abstract**

**Background:** patients with liver cirrhosis (LC) undergoing cardiac surgery (CS) face perioperative high mortality and morbidity, but extensive studies on this topic are lacking.

**Methods:** All adult patients with LC undergoing a CS procedure between 2000-2017 at ten Italian Institutions were included in this retrospective cohort study. LC was classified according to preoperative Child-Turcotte-Pugh (CTP) Score and Model for End-Stage Liver Disease (MELD) score. Early and medium-term outcomes analysis was performed in the overall population and according to CTP classes.

**Results:** The study population included 144 patients (mean age:  $66 \pm 9$  years; male=69%). Ninety-eight, 20 and 26 patients were in CTP class-A, in early (MELD  $<12$ ) or advanced (MELD  $>12$ ) CTP class-B respectively. The main LC etiologies were viral (43%) and alcoholic (36%). Liver-related clinical presentation (ascites, esophageal varices and encephalopathy) and laboratory values (EGFR, serum albumin and bilirubin, platelet count) significantly worsened across the CTP-classes ( $p=.001$ ). CABG or valve surgery (87% bioprosthesis) were performed in 36% and 50% respectively. Postoperative complications (especially AKI, liver complication and LOS) significantly worsened in advanced CTP class-B ( $p=.001$ ). Notably, observed mortality was 3 or 4-fold higher than the EuroscoreII-predicted mortality, in the overall population, and in the subgroups. At Kaplan-Meier analysis, 1- and 5-years cumulative survival in the overall population was  $82 \pm 3\%$  and  $77 \pm 4\%$  respectively. The 5-years survival in CTP class A, early- and advanced-B was  $72 \pm 5\%$ ,  $68 \pm 11\%$  and  $61 \pm 10\%$  respectively ( $p=.238$ ).

**Conclusions:** CS outcomes in patients with LC are significantly affected in relation to the extent of preoperative liver dysfunction, but in the early CTP classes medium-term survival is acceptable. Further analysis are needed to better estimate the preoperative risk stratification of these patients.

Liver cirrhosis (LC) incidence is growing in the western countries, especially due to a significant increase in alcoholic and metabolic syndrome etiologies(1). The prevalence of LC in patients undergoing cardiac surgery (CS) is reported to be as low as 0.2–0.3%, accounting for over 6000 cases worldwide yearly. However, in recent years, increased longevity has contributed to the increased incidence of cardiovascular disease in cirrhotic patients, so that an increasing number of CS procedures are expected. Despite LC is not included within the most important risk scores(2), it is considered a major preoperative risk factor in CS, depending on the severity of preoperative liver disease(3). Few published studies on this topic concluded that CS is reasonably safe in patients with mild to moderate liver dysfunction(4). However, detailed analysis of the postoperative outcomes in these patients are lacking, and recommendations whether to perform CS remain unclear. The present study aimed to report the early and long-term results of a consecutive multicenter series of patients with LC undergoing CS, to find predictors of outcomes and to assess the relevance of EuroSCORE, CTP class and the MELD score in terms of prediction of surgical morbidity, mortality and medium-term survival.

## **Material and Methods**

### *Study Design and Inclusion Criteria*

The **CA**rdiac **S**urgery in **pa**Tients with **liv**ER cirrhosis (CASTER) study is a retrospective observational cohort study, including all adult patients affected by LC undergoing a CS procedure between January 2000 and December 2017. Exclusion criteria included patients aged <18 years, or patients treated for acute aortic dissection, heart transplant or LVAD implantation.

### *Patient Cohort and Data Collection*

Ten Italian centers participated in the study. All the participant centers are tertiary care hospitals and referral centers for cardiac surgery, and four centers (40%) are University Hospitals. Preoperative, operative, and postoperative data were collected from institutional databases. Follow-up was achieved through direct or telephone interview with survivors, with relatives or with general

practitioners. Ethics committee approval was obtained initially from the coordinating center (IRCCS Policlinico San Donato, study code n° 36/INT/2017) and subsequently from each participating site. Surgical procedures, including the use of extracorporeal circulation (ECC) in myocardial revascularization or type of implanted prosthesis were based solely on center or surgeon preference.

### *Study Outcomes*

The outcomes of the study were the following: 1) Primary outcome: 30-days or in-hospital all-cause mortality. 2) Secondary outcomes: a) incidence of major postoperative morbidity and b) long-term freedom from all-cause mortality. Primary and secondary outcomes were defined according to the STS-AATS-EACTS Guidelines for reporting mortality and morbidity after cardiac interventions(5). Postoperative hepatic dysfunction was defined according to the International Study Group of Liver Surgery(6).

### *Liver Cirrhosis Score definition*

The diagnosis of LC was based on clinical history and physical stigmata consistent with findings of abdominal imaging studies(coarsened heterogeneous echo pattern, increased parenchymal echogenicity, and nodularity of the liver surface). The severity of LC was graded according to the Child classification(7) and MELD score(8). Child-Turcotte-Pugh (CTP) score was calculated by using the following variables: severity of hepatic encephalopathy(grade 1-3), ascites(absent, mild, moderate), total bilirubin(mg/dL), serum albumin(gm/dL), and prothrombin time(seconds). CTP classification was defined based on the resulting score(A: 5-6; B: 7-9; C: 10-15). The MELD score was calculated using the formula published by Kamath(8):  $MELD\ score = 3.8 * \log_e(bilirubin\ [mg/dL]) + 11.2 * \log_e(international\ normalized\ ratio) + 9.6 * \log_e(creatinine\ [mg/dL]) + 6.4 * (etiology: 0\ if\ cholestatic\ or\ alcoholic; 1\ otherwise)$ . The combined use of CTP and MELD classification has been recently advocated for enhanced risk stratification of cirrhotic patients undergoing general surgery(9).

### *Statistical Analysis*

Normality distribution of the continuous variables was tested with the Skewness and Kurtosis Test. Results were presented as mean values $\pm$ SD or median(IQR). Parametric(1-way analysis of variance) and nonparametric(Kruskal-Wallis Test) tests were used for comparison of continuous variables. The Fisher's exact test was used for comparison of categorical variables. A p value  $<0.05$  was considered statistically significant. Potential predictors of 30-days mortality and major morbidity were tested with multivariate logistic regression analysis, using a stepwise logistic regression model. Calibration of the model was assessed with the Hosmer-Lemeshow goodness-of-fit test. The predictive value of risk scores (EuroscoreII, CTP and MELD) on 30-days mortality was evaluated with the ROC curve analysis. Survival curves were calculated starting from the date of surgery. Kaplan-Meier analysis with the Log-Rank test was applied for estimation of medium-term survival across the study groups. Independent predictors of long-term mortality were estimated by means of multivariable Cox regression analysis. Schoenfeld residuals Test was used to check the proportional-hazard assumption for all categorical covariates. Statistical calculations were performed using a computerized statistical program (SPSS Statistics, version 22.0; SPSS Inc, Chicago, Illinois, USA).

### **Results**

The final study population consisted of 144 patients (0.15% of all the CS procedures performed in the study period), all in CTP class A (98 patients) and B (46 patients). Further, patients in CTP class B were dichotomized by MELD scores into early ( $\text{MELD} \leq 12$ , 20 patients) and advanced ( $\text{MELD} > 12$ , 26 patients). The MELD score cutoff point of 12 has been selected according to previous studies investigating mortality in patients with LC undergoing CS(10). No patients in CTP Class C were collected in the present series, probably because, due to severe liver dysfunction, they were deemed unsuitable for CS.

### *Temporal trend over the study period*

For temporal trend analysis, the study period was divided into six three-year periods(**Figure 1**). The rate of patients with LC undergoing CS increased 6-fold during the study period, from 0.06% to 0.30% (7 to 45 patients). The preoperative LC severity( $p=.534$ ) and the CS risk estimation( $p=.336$ ) were nearly constant over the years. Despite this, in-hospital mortality significantly increased over the study period, starting at 2% in the first years and peaking at 10% in the most recent years( $p=.045$ ).

#### *Preoperative patients' profile*

Preoperative characteristics in the three CTP classes are depicted in **Table 1**. Overall, the subgroups of patients were comparable as regards the clinical characteristics and cardiac risk factors. We observed a trend towards a worse clinical profile in advanced class B patients, without statistical significance. LC etiology in the overall population was mainly alcoholic (36%) and viral (43%), without significant differences among CTP classes. Preoperative LC severity significantly affected liver-related clinical presentation at admission as symptoms and laboratory values significantly worsened across the three CTP classes (**Table 2**). Median CTP score was 6 in class A and 8 in class B, but median MELD score significantly increased from 9 in class A to 10 and 18 in early and advanced class B respectively( $p=.001$ ).

#### *Perioperative and postoperative outcomes*

Perioperative characteristics are depicted in **Table 3**. CS procedures included CABG (36%), valvular surgery(50%) and aortic procedures (14%). Interestingly the rate of valve surgery significantly increased in advanced LC ( $p=.001$ ), suggesting an increasing role of valvular-related congestion on more severe liver dysfunction. The ECC was used in 74% of the patients, and a biological valve was implanted in 75% of valvular procedures, without significant differences among the study groups. Postoperative complications rate in the overall population was 32% with a significant increase between CTP classes( $p=.005$ ). Nearly 70% of the patients were transfused postoperatively(median transfused units=4), without significant differences between CTP classes.

Infections(6%), acute kidney injury(AKI-12%) and hepatic decompensation(15%) were the most common postoperative complications, with a significant increase among CTP classes( $p=.001$ ; **Figure 2**). At logistic regression analysis, CTP score( $OR=1.34$ , 95%CI:1.05-1.70,  $p=.016$ ) preoperative chronic renal failure( $OR=2.37$ , 95%CI:1.06-5.27,  $p=.034$ ) and preoperative EF( $OR=4.32$ , 95%CI:0.92-0.99,  $p=.006$ ) resulted independent risk factors for postoperative complications [Hosmer-Lemeshow: chi-square=9.34,  $p=.32$ ; AUC=0.72(95%CI:0.63-0.81)].

Finally, overall 30-days mortality was 15%(22 patients), without significant differences among the three groups (**Table 4**). However, in CTP Class B patients with very advanced LC (MELD score >18,  $n^{\circ}$  8 patients) mortality peaked to 37%, even if the small number of observation limited statistical significance ( $p=.15$ ). The cause of death included hepatic decompensation with multisystem organ failure(8 patients, 36%), renal failure(6 patients, 27%), sepsis(5 patients, 23%) and respiratory failure(3 patients, 14%). Logistic regression analysis identified preoperative bilirubin( $OR=1.10$ , 95%CI:1.01-1.20,  $p=.012$ ), COPD( $OR=2.46$ , 95%CI:1.91-6.56,  $p=.003$ ) and aortic procedure( $OR=4.32$ , 95%CI:1.56-8.67,  $p=.001$ ) as independent risk factors for 30-days mortality[Hosmer-Lemeshow: chi-square=9.03,  $p=.34$ ; AUC=0.71(95%CI:0.58-0.83)]. Notably, observed mortality was significantly 3 or 4-fold higher than the EuroscoreII and STS score-predicted mortality, in the overall population, as well as in the subgroup analysis based on LC classes and type of surgical procedures (**Figure 3**). At ROC curve analysis, neither EuroSCORE-II nor CTP and MELD scores provided optimal discrimination in predicting 30-days mortality (**Figure 4**).

#### *Medium-term outcomes*

Median follow-up in the overall population was 51(10-88) months, without significant differences among the CTP classes( $p=.647$ ). Mid-term survival of the overall population(including 30-days mortality) was  $82\pm3\%$  at 1 year,  $77\pm4\%$  at 5 years and  $63\pm5\%$  at 8 years. The 1-year survival for CTP class A, early B and advanced B was  $87\pm4\%$ ,  $75\pm9\%$  and  $71\pm9\%$  respectively. The 5-years survival in the same classes was  $72\pm5\%$ ,  $68\pm11\%$  and  $61\pm10\%$ ( $p=.238$ ; **Figure 5**). At Cox

regression analysis, preoperative serum albumin[HR=0.75(95%CI: 0.69-0.84); p=.005] and perioperative transfusion[HR=2.28(95%CI: 1.43-2.86); p=.001] resulted independent predictors of long-term mortality(**Figure6**).

### **Comment**

Patients with LC undergoing various surgical procedures are at an increased risk of surgery and anesthesia-related complications(11,12). In the present experience, overall 30-days mortality was 15%, ranging between 13%-20% according to preoperative liver dysfunction. This is consistent with the reported perioperative mortality in cirrhotic patients, ranging between 25% and 70% in the most advanced class of liver dysfunction(13). Despite a clear indication in cirrhotic patients is lacking, it is generally accepted that CS can be done safely in patients with CTP class-A and early-B. Moreover, the risk of mortality is higher in patients with CTP class-B with a MELD score >13 and nearly prohibitive in patients with CTP class-C(14). Accordingly, in the present experience, despite perioperative mortality and overall incidence of complications increased constantly among the CTP classes, only patients in CTP advanced class B showed significantly worsen risk profile and clinical outcome compared to the previous classes. Taking this into account, a careful preoperative evaluation in this group of patients is mandatory as clinical preoperative optimization (coagulopathy, ascites and malnutrition) can improve postoperative outcomes(15).

### *Surgical risk assessment*

As previously reported, one of the most striking findings of the present experience is that operative mortality is completely unrelated to the predicted mortality based on CS risk scores. Because mortality in these patients is mainly associated with liver function, liver scores such as the MELD or CTP score have been evaluated to predict post CS mortality, but the results in limited monocentric series are conflicting(16). Other researchers reported that single liver parameters (serum bilirubin, albumin, cholinesterase or platelets count) rather than LC scores are significant determinants of postoperative outcomes(17). In the present experience LC scores didn't prove a



significant superiority compared to EuroscoreII in predicting 30-days mortality (**Figure 4**). Furthermore, at multivariable logistic analysis, serum bilirubin proved to be the only liver-related risk factor predicting perioperative mortality. This is consistent with the series from Lin and colleagues(18), who found that serum bilirubin was a strong predictor of early and 5-years mortality post CS. Of course, our analyses could have been underpowered due to the limited sample size. Unfortunately, two recent population-based cohort studies(19,20) including nearly eight thousands patients with LC undergoing CS were unable to collect preoperative liver information, so that the predictive role of CTP/MELD scores on perioperative outcomes could not be assessed.

#### *Perioperative morbidity*

Mortality after CS in cirrhotic patients is strictly related to an increased incidence of perioperative complications like infections, renal failure, hepatic decompensation and bleeding. Indeed, postoperative morbidities remain a major issue in this population. Previous studies have documented complication rates ranging from 28% and 69%(21). Similarly, in the present study, postoperative complications ranged between 28% and 43%, depending on preoperative liver dysfunction. The rate of perioperative transfusions in our study was nearly 70%, without significant differences among CTP classes. Several reasons account for a higher requirement of perioperative transfusion in these patients. LC is often accompanied by anemia and thrombocytopenia due to poor nutritional status, splenomegaly and bleeding from varices. Additionally, impaired coagulation may occur in cirrhotic patients since many of the coagulation factors are synthesized by the liver(22). In the present experience blood transfusions were not an independent predictor of early mortality, probably because their net effect was overcome by the weight of liver dysfunction. However, transfusion requirement was an independent predictor of long-term mortality, and this is consistent with the reported literature in CS and in patients with LC(23,24).

AKI, cardiac dysfunction and liver decompensation are interrelated complications, commonly occurring in cirrhotic patients undergoing CS. Advanced LC is often accompanied by various

degree of cardiomyopathy, characterized by diastolic dysfunction along with impaired inotropic, and chronotropic incompetence, which can translate in postoperative cardiac impairment (12-21% in the present study). Postoperative cardiac dysfunction results in elevated central venous pressure, which plays a significant role in the pathogenesis of hepatorenal syndrome and AKI(8-23% in our series)(25). Furthermore, physiologic challenges associated with CPB, including hypoperfusion, hemodilution and catecholamine release are poorly tolerated in patients with liver disease(26). Particularly, CPB-related visceral hypoperfusion, can contribute to hepatorenal syndrome, liver decompensation (5-31% in the present study) and bowel ischemia with bacterial translocation and sepsis. It should be noted that the rate of perioperative hepatic and renal complications showed a significant decrease among the study periods. This improvement probably reflects the advances in the perioperative management of these patients achieved during the last decade.

#### *Long-term outcomes*

The overall 5-year survival of the study population was 77%, ranging from 72% to 61% among CTP classes. In the present experience, the impact of preoperative liver dysfunction on long-term survival after CS seems less relevant compared to other published experience(27). Of note, this fact can be related to the exclusion of cirrhotic patients with CTP class C, who carry the worse prognosis. On the other hand, our experience suggest that, if patients are able to survive the perioperative period, medium term survival is excellent, at least in CTP early classes, and cirrhotic patients with MELD lower than 12-15 should not be refused CS, advocating long-term dismal prognosis. In our multivariable Cox analysis, we found albumin was an independent predictor of long-term mortality. Lower albumin level is a marker of poor nutritional status in patients with LC, and can help in discriminate patients with minimal hepatic reserve who carry a poor prognosis after CS(28). Furthermore, hypoalbuminemia together with higher perioperative blood transfusion requirements are strongly associated to infection and sepsis, thus resulting in poor early and long-term outcomes after CS(29).

### *Study Limitation*

This was a retrospective observational multicenter study, and patient management was performed according to individual center strategy or protocol, with heterogeneous approaches, therefore making definitive conclusions inapplicable. In designing the study, we did not collect a control group of patients without LC. There are several large population-based studies investigating the independent role of LC on perioperative morbidity and mortality. On the contrary, our aim was to best characterize the cirrhotic patients in order to ascertain the predictive role of liver-related factors on post CS outcomes. A more sophisticated analysis on the subgroups of surgical procedures, as well on the role of ECC is lacking in the present study, and it will be the object of a future research. Finally, our sample size is significantly smaller compared to recent population-based cohort studies. However, despite these latter studies are strengthened by the elevated number of included patients, many specific information regarding liver severity assessment are lacking. Taking into account these limitations, the present study was able to collect precise LC characterization, thus spreading some light on the risk assessment of CS in these patients that deserve further investigations.

### *Conclusion*

In conclusion, the present study confirms that cirrhotic patients undergoing CS experience a significant high perioperative mortality and morbidity. CS outcomes in these patients are unrelated to the predicted outcomes based on the conventional cardiac risk factors and the adjunctive role of liver risk model (CTP and MELD) is debatable. Despite increased perioperative mortality, at least in the early CTP classes medium-term survival is excellent. Further analysis are needed to expand our preliminary observation and to evaluate if the use of more sophisticated liver imaging (i.e. liver stiffness assessment by transient elastography) can better estimate the preoperative risk stratification of these patients.

|                    | <b>Total<br/>Population</b> | <b>CTP Class<br/>A</b> | <b>CTP Class B<br/>Early<br/>(MELD &lt; 12)</b> | <b>CTP Class B<br/>Advanced<br/>(MELD&gt;12)</b> | <b>P<br/>Value</b> |
|--------------------|-----------------------------|------------------------|---|--|--------------------|
| <b>N° Patients</b> | 144                         | 98                     | 20  | 26   |                    |
| Mean Age           | 66±9                        | 66±9                   | 68±8  | 65±11  | .527               |
| Male Gender        | 100(69%)                    | 74(75%)                | 10(50%)   | 16(61%)  | <b>.049</b>        |

**Table 1:** Preoperative characteristic in the overall population and in the CTP classes.

|                              |           |           |           |           |             |
|------------------------------|-----------|-----------|-----------|-----------|-------------|
| BSA                          | 1.85±0.18 | 1.9±0.17  | 1.8±0.18  | 1.8±0.22  | .184        |
| BMI                          | 24(23-27) | 25(23-27) | 24(23-30) | 23(21-26) | .074        |
| Median EF (%)                | 55(47-60) | 56(45-60) | 57(55-60) | 55(45-62) | .597        |
| Median TAPSE                 | 20(18-21) | 22(20-23) | 20(19-21) | 17(15-19) | <b>.005</b> |
| Pulmonary HPT <sup>§</sup>   | 69(48%)   | 43(44%)   | 9(45%)    | 17(65%)   | <b>.039</b> |
| <b>Clinical Presentation</b> |           |           |           |           |             |
| <i>Hypertension</i>          | 88(61%)   | 57(58%)   | 15(75%)   | 16(61%)   | .371        |
| <i>Dyslipidemia</i>          | 46(32%)   | 29(30%)   | 4(20%)    | 13(50%)   | .065        |
| <i>Diabetes</i>              | 63(44%)   | 43(44%)   | 8(40%)    | 12(46%)   | .916        |
| <i>Chronic Renal Failure</i> | 79(55%)   | 50(51%)   | 8(40%)    | 21(81%)   | <b>.009</b> |
| <i>CVA</i>                   | 16(11%)   | 10(10%)   | 0(0%)     | 6(23%)    | <b>.042</b> |
| <i>COPD</i>                  | 41(28%)   | 27(28%)   | 6(30%)    | 8(31%)    | .937        |
| <i>Previous CS</i>           | 11(8%)    | 5(5%)     | 1(5%)     | 5(19%)    | <b>.049</b> |
| <i>NYHA &gt;II</i>           | 12(8%)    | 9(9%)     | 1(5%)     | 2(8%)     | .821        |
| <b>Preoperative Therapy</b>  |           |           |           |           |             |
| <i>ACE inhibitors</i>        | 27(19%)   | 21(21%)   | 3(15%)    | 3(12%)    | .464        |
| <i>Diuretics</i>             | 31(21%)   | 16(16%)   | 5(25%)    | 10(38%)   | <b>.023</b> |
| <i>Oral Anticoagulant</i>    | 7(5%)     | 5(5%)     | 1(5%)     | 1(4%)     | .965        |
| <i>Statins</i>               | 10(7%)    | 8(8%)     | 1(5%)     | 1(4%)     | .267        |

§ Pulmonary Hypertension defined as Systolic pulmonary pressure > 45 mmHg

|                           | <b>Total<br/>Population</b> | <b>CTP Class<br/>A</b> | <b>CTP Class B<br/>Early<br/>(MELD &lt; 12)</b> | <b>CTP Class B<br/>Advanced<br/>(MELD&gt;12)</b> | <b>P<br/>Value</b> |
|---------------------------|-----------------------------|------------------------|---|--|--------------------|
| <b>Cirrhosis Etiology</b> |                             |                        |   |  | <b>.627</b>        |
| <i>Alcoholic</i>          | 48(33%)                     | 32(33%)                | 6(30%)  | 10(38%)  |                    |
| <i>Viral</i>              | 64(45%)                     | 42(43%)                | 9(45%)  | 13(50%)  |                    |
| <i>Auto-immune</i>        | 20(14%)                     | 16(16%)                | 2(10%)  | 2(8%)  |                    |
| <i>Cardiogenic</i>        | 12(8%)                      | 8(8%)                  | 3(15%)  | 1(4%)  |                    |
| Ascites                   | 39(27%)                     | 20(20%)                | 3(15%)  | 16(61%)  | <b>.001</b>        |
| Esophageal Varices        | 58(40%)                     | 35(36%)                | 8(40%)  | 15(58%)  | .127               |
| Encephalopathy            | 14(10%)                     | 6(6%)                  | 2(10%)  | 6(23%)   | .058               |
| <b>Laboratory values</b>  |                             |                        |   |  |                    |
| <i>EGFR</i>               | 63±24                       | 64±23                  | 72±22   | 53±24  | <b>.019</b>        |
| <i>Albumin</i>            | 3.4(2.8-4)                  | 3.7(3.1-4.1)           | 2.8(2.5-3.6)                                    | 2.5(2.3-3.1)                                     | <b>.001</b>        |
| <i>Bilirubin</i>          | 1.2(0.7-2.0)                | 1.1(0.6-1.7)           | 1.3(0.8-2.6)                                    | 1.9(1.1-3.2)                                     | <b>.001</b>        |
| <i>Platelet</i>           | 134±73                      | 146±80                 | 120±42  | 98±46  | <b>.007</b>        |
| <i>INR</i>                | 1.2(1.1-1.3)                | 1.1(1.05-1.2)          | 1.2(1.15-1.4)                                   | 1.35(1.2-1.5)                                    | <b>.021</b>        |
| Child Score               | 6(5-7)                      | 6(5-6)                 | 8(7-8)  | 8(7-9)   | <b>.001</b>        |
| MELD Score                | 10(8-15)                    | 9(8-12)                | 10(8-12)  | 18(16-20)  | <b>.001</b>        |

**Table 2:** Liver Cirrhosis characteristics in the study population.

**Table 3:** Operative characteristic in the overall population and in the CTP classes.

|                          | <b>Total<br/>Population</b> | <b>CTP Class<br/>A</b> | <b>CTP Class B<br/>Early<br/>(MELD &lt; 12)</b> | <b>CTP Class B<br/>Advanced<br/>(MELD &gt;12)</b> | <b>P Value</b> |
|--------------------------|-----------------------------|------------------------|---|---|----------------|
| <b>N° Patients</b>       | 144                         | 98                     | 20  | 26  |                |
| Median Euroscore II      | 3.1(1.4-7.1)                | 1.7(1.2-3.1)           | 3(1.4-6.1)                                      | 8.5(2-12)   | <b>.004</b>    |
| CS Procedure             |                             |                        |   |   |                |
| CABG                     | 52(36%)                     | 44(45%)                | 4(20%)  | 4(15%)  | <b>.001</b>    |
| <i>OPCABG</i>            | 39(75%)                     | 31(70%)                | 4(100%)   | 4(100%)   |                |
| Valvular Surgery         | 72(50%)                     | 40(41%)                | 13(65%)   | 19(73%)   | <b>.001</b>    |
| <i>Valve Replacement</i> | 50(69%)                     | 33(83%)                | 6(46%)  | 11(58%)   |                |
| <i>Valve Repair</i>      | 20(28%)                     | 6(15%)                 | 6(46%)  | 8(42%)  |                |
| <i>Endocarditis</i>      | 2(3%)                       | 1(2%)                  | 1(8%)   | -   |                |
| Aortic Surgery           | 20(14%)                     | 14(14%)                | 3(15%)  | 3(12%)  | .256           |
| <i>Bentall/ David</i>    | 8(40%)                      | 6(43%)                 | 2(67%)  | -   |                |
| <i>AA Replacement</i>    | 12(60%)                     | 8(57%)                 | 1(33%)  | 3(100%)   |                |
| ECC use                  | 105(74%)                    | 67(68%)                | 16(80%)   | 22(84%)   | .162           |
| Median ECC time          | 97(70-127)                  | 98(74-127)             | 83(66-110)                                      | 104(70-186)                                       | .674           |
| Median Clamp time        | 68(46-92)                   | 71(47-95)              | 62(46-71)                                       | 74(48-136)  | .277           |
| Median N° of CABG        | 2(1-4)                      | 2(2-4)                 | 2(1.5-3.5)                                      | 3(2-3)  | .997           |
| Biological Valve         | 54(75%)                     | 31(77%)                | 11(85%)   | 16(84%)   | .572           |

**Abbreviations:** AA= Ascending Aorta; ECC=Extra-Corporeal Circulation; Continuous variable: mean±SD or Median(IQR). Dichotomous variable: n°(%)

**Table 4:** Perioperative characteristic in the overall population and in the CTP classes

|                              | <b>Total<br/>Population</b> | <b>CTP Class<br/>A</b> | <b>CTP Class B<br/>Early<br/>(MELD &lt; 12)</b> | <b>CTP Class B<br/>Advanced<br/>(MELD &gt;12)</b> | <b>P Value</b> |
|------------------------------|-----------------------------|------------------------|---|---|----------------|
| Inotropic support            | 61(42%)                     | 41(42%)                | 6(30%)  | 14(54%)   | .264           |
| IABP Rate                    | 8(6%)                       | 6(6%)                  | 1(5%)   | 1(4%)   | .897           |
| Transfusion Rate             | 101(70%)                    | 69(70%)                | 12(60%)   | 20(77%)   | .459           |
| Total Transfused Units       | 4(0-7)                      | 2(0-5)                 | 3(0-8)  | 5(2-9)  | .581           |
| <i>RBC Units</i>             | 2(0-4)                      | 1(0-4)                 | 2(0-5)  | 3(1-6)  | .342           |
| <i>FFP Units</i>             | 1(0-1)                      | 1(0-1)                 | 1(0-1)  | 1(0-2)  | .766           |
| <i>PTL Units</i>             | 1(0-1)                      | 1(0-2)                 | 1(0-2)  | 1(0-4)  | .717           |
| Median ICU stay (days)       | 2(1-5)                      | 2(1-5)                 | 2(1-3)  | 4(2-9)  | .154           |
| <b>In-Hospital Mortality</b> | 22(15%)                     | 13(13%)                | 4(20%)  | 5(19%)  | .617           |
| CABG                         | 6(11%)                      | 6(14%)                 | 0(0%)   | 0(0%)   | .343           |
| <i>On-pump CABG</i>          | 3(23%)                      |                        |   |   |                |
| <i>OP-CABG</i>               | 3(8%)                       |                        |   |   |                |
| Valvular Surgery             | 9(12%)                      | 4(10%)                 | 2(15%)  | 3(16%)  | .773           |
| Aortic Surgery               | 7(35%)                      | 3(21%)                 | 2(67%)  | 2(67%)  | .151           |

**Abbreviations:** FFP=Fresh Frozen Plasma; PTL=Platelets; RBC=Red Blood Cells. Continuous variable: mean±SD or Median (IQR). Dichotomous variable: n° (%)



**Figure Legends**

**Figure 1:** Temporal trend of patients with LC submitted to CS procedures.

**Figure 2:** Perioperative complications rate in the CTP classes.

**Figure 3:** Comparison between EuroscoreII-predicted and observed 30-days mortality(with 95% CI).

**Figure 4:** Predictive role of risk factors on 30-days mortality at ROC analysis. A) EuroscoreII; B) CTP score; C) MELD Score; D) Risk Score Comparison.

**Figure 5:** Long-term cumulative survival according to CTP classes.

**Figure 6:** Long-term adjusted survival probability according to perioperative transfusion requirement. Cox Regression analysis.

## References

1. Wong RJ,Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. *World J Hepatol* 2014;6:263-273.
2. Geissler HJ,Holz P,Marohl S,et Al. Risk stratification in heart surgery: Comparison of six score systems. *Eur J Cardiothorac Surg* 2000;17:400-406.
3. Macaron C,Hanouneh IA,Suman A,Lopez R,Johnston D,Carey WW. Safety of cardiac surgery for patients with cirrhosis and Child-Pugh scores less than 8. *Clin Gastroenterol Hepatol* 2012;10:535–9.
4. Vanhuysse F,Maureira P,Portocarrero E,et Al., Cardiac surgery in cirrhotic patients: results and evaluation of risk factors, *Eur. J. Cardiothorac. Surg.* 2012;42:293–299.
5. Akins CW,Miller DC,Turina MI et Al;STS;AATS;EACTS. Guidelines for reporting mortality and morbidity after cardiac valve interventions. *Ann Thorac Surg.* 2008;85(4):1490-5.
6. Rahbari NN, Garden OJ, Padbury R et Al.Post hepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery(ISGLS).Surgery.2011;149(5):713-24.
7. Child CGIII,Turcott JG. Surgery and portal hypertension. In:Child CGIII,Editor. The liver and portal hypertension. Philadelphia, PA:Saunders,1964:50-58.
8. Kamath PS,Wiesner RH,Malinchoc M,et Al. A Model to Predict Survival in Patients With End-Stage Liver Disease. *Hepatology* 2001;33:464-470.
9. Farnsworth N,Fagan SP,Berger DH,Awad SS. Child–Turcotte–Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients, *Am. J. Surg.* 2004;188:580–583.
10. Morisaki A,Hosono M,Sasaki Y,et Al. Risk factor analysis in patients with liver cirrhosis undergoing cardiovascular operations, *Ann. Thorac. Surg.* 2010;89:811–817.
11. Friedman LS. The risk of surgery in patients with liver disease. *Hepatology* 1999;29:1617-1623

12. O'Leary JG,Yachinski PS,Friedman LS. Surgery in the patient with liver disease, Clin. Liver Dis. 2009;13:211–231.
13. Lopez-Delgado JC,Esteve F,Javierre C,et Al. Predictors of long-term mortality in patients with cirrhosis undergoing cardiac surgery. J Cardiovasc Surg 2015;56(4):647-54.
14. Modi A,Vohra HA,Barlow CW. Do patients with liver cirrhosis undergoing cardiac surgery have acceptable outcomes? Interact CardioVasc Thorac Surg 2010;11:630–4.
15. Abbas N,Makker J,Abbas H,Balar B. Perioperative Care of Patients With Liver Cirrhosis: A Review. Health Serv Insights.2017;24:10.
16. Suman A,Barnes DS,Zein NN,Levinthal GN,Connor JT,Carey WD. Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores. Clin Gastroenterol Hepatol 2004;2:719–723.
17. An Y,Xiao YB,Zhong QJ. Open-heart surgery in patients with liver cirrhosis: indications, risk factors, and clinical outcomes. Eur Surg Res 2007;39:67-74.
18. Lin CH,Hsu RB. Cardiac surgery in patients with liver cirrhosis: risk factors for predicting mortality. World J Gastroenterol. 2014;20(35):12608-14.
19. Chou AH,Chen TH,Chen CY,et Al. Long-Term Outcome of Cardiac Surgery in 1,040 Liver Cirrhosis Patient–Nationwide Population-Based Cohort Study. Circ J. 2017;81(4):476-484.
20. Gopaldas RR,Chu D,Cornwell LD,et Al. Cirrhosis as a moderator of outcomes in coronary artery bypass grafting and off-pump coronary artery bypass operations: a 12-year population-based study. Ann Thorac Surg. 2013;96(4):1310-1315.
21. Hayashida N,Shoujima T,Teshima H,et Al. Clinical outcome after cardiac operations in patients with cirrhosis. Ann Thorac Surg 2004;77:500–505.
22. Liu P,Hum J,Jou J,Scanlan RM,Shatzel J. Transfusion strategies in patients with cirrhosis. Eur J Haematol. 2020;104(1):15-25.

23. Koch CG, Li L, Duncan AI, et Al. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. *Ann Thorac Surg* 2006;81:1650–7.
24. Johnson KM, Newman KL, Green PK, et Al. Incidence and Risk Factors of Postoperative Mortality and Morbidity After Elective Versus Emergent Abdominal Surgery in a National Sample of 8193 Patients With Cirrhosis. *Ann Surg*. 2019 Oct 23.
25. Theodoridou E, Krag A, Bendtsen F, Møller S, Burroughs AK. Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis. *Liver Int* 2012;32:1327-1332.
26. Mathie RT. Hepatic blood flow during cardiopulmonary bypass. *Crit Care Med* 1993;21:S72-S76.
27. Filsoufi F, Salzberg SP, Rahmanian PB, et Al. Early and late outcome of cardiac surgery in patients with liver cirrhosis, *Liver Transpl*. 2007;13:990–995.
28. Engelman DT, Adams DH, Byrne JG, et Al. Impact of body mass index and albumin on morbidity and mortality after cardiac surgery. *J Thorac Cardiovasc Surg* 1999;118:866-873.
29. Oliver E, Carrio ML, Rodríguez-Castro D, et Al. Relationships among haemoglobin level, packed red cell transfusion and clinical outcomes in patients after cardiac surgery. *Intensive Care Med* 2009;35:1548-1555.

